Role for rexinoids is expanding

April 1, 2004

Waikoloa, Hawaii - Rexinoids such as bexarotene have promise as an adjunct to other immune response modifiers in the treatment of patients with progressive cutaneous T-cell lymphoma (CTCL), according to Jacqueline M. Junkins-Hopkins, M.D. Such therapies are typically used in combination with interferon-alpha as well as with psoralen ultraviolet-A (PUVA) and extracorporeal photopheresis (ECP).